Фактор-інгібітор (Factor-Inhibitor Assay)

Референтні значення:

Якщо після адекватної інфузії VII, VIII, IX, XI і V кровотечі продовжуються, показаний аналіз на інгібітор фактора. Хоча майже всі прокоагулянти мають інгібітор, інгібітор фактора VIII є найбільш поширеним.

За нормальних обставин ніяких інгібіторів фактора немає.

Інтерпретація

Факторні інгібітори вимірюються в одиницях Бетесди (BU).

Вони присутні в інгібіторах фактора VIII, які є антитілами до IgG проти фактора VIII, зустрічаються при гемофілії А (алоантитіла). Як аутоантитіла вони зазвичай виникають спонтанно, особливо у літнього населення, але вони також зустрічаються при вагітності та аутоімунних захворюваннях.

ДЖЕРЕЛА:

  1. Ewing NP, Kasper CK. In vitro detection of mild inhibitors to factor VIII in hemophilia. Am J Clin Pathol. 1982 Jun. 77(6):749-52. [Medline].
  2. Warn-Cramer BJ, Rao LV, Maki SL, Rapaport SI. Modifications of extrinsic pathway inhibitor (EPI) and factor Xa that affect their ability to interact and to inhibit factor VIIa/tissue factor: evidence for a two-step model of inhibition. Thromb Haemost. 1988 Dec 22. 60(3):453-6. [Medline].
  3. Broze GJ Jr, Warren LA, Novotny WF, Higuchi DA, Girard JJ, Miletich JP. The lipoprotein-associated coagulation inhibitor that inhibits the factor VII-tissue factor complex also inhibits factor Xa: insight into its possible mechanism of action. Blood. 1988 Feb. 71(2):335-43. [Medline].
  4. Ameri A, Kuppuswamy MN, Basu S, Bajaj SP. Expression of tissue factor pathway inhibitor by cultured endothelial cells in response to inflammatory mediators. Blood. 1992 Jun 15. 79(12):3219-26. [Medline].
  5. Sandset PM, Abildgaard U, Larsen ML. Heparin induces release of extrinsic coagulation pathway inhibitor (EPI). Thromb Res. 1988 Jun 15. 50(6):803-13. [Medline].
  6. Monroe DM HM, Roberts HR. Molecular Biology and Biochemistry of the Coagulation Factors and Pathways of Hemostasis. Prchal JT KK, Lichtman MA, Kipps TJ, Seligsohn U, ed. Williams Hematology. 8th ed. New York: McGraw-Hill; 2010.
  7. Griffith MJ. Measurement of the heparin enhanced-antithrombin III/thrombin reaction rate in the presence of synthetic substrate. Thromb Res. 1982 Feb 1. 25(3):245-53. [Medline].
  8. Sheffield W WY, Blajchman M ed. KA High HR, ed. Antithrombin: Structure and function. Marcel Dekker Molecular Basis of Thrombosis and Hemostasis. New York: 1995.
  9. Pizzo SV. Serpin receptor 1: a hepatic receptor that mediates the clearance of antithrombin III-proteinase complexes. Am J Med. 1989 Sep 11. 87(3B):10S-14S. [Medline].
  10. Han X, Fiehler R, Broze GJ Jr. Isolation of a protein Z-dependent plasma protease inhibitor. Proc Natl Acad Sci U S A. 1998 Aug 4. 95(16):9250-5. [Medline].
  11. Yin ZF, Huang ZF, Cui J, Fiehler R, Lasky N, Ginsburg D. Prothrombotic phenotype of protein Z deficiency. Proc Natl Acad Sci U S A. 2000 Jun 6. 97(12):6734-8. [Medline].
  12. Fujimaki K, Yamazaki T, Taniwaki M, Ichinose A. The gene for human protein Z is localized to chromosome 13 at band q34 and is coded by eight regular exons and one alternative exon. Biochemistry. 1998 May 12. 37(19):6838-46. [Medline].
  13. Chen P, Jani J, Streiff MB, Zheng G, Kickler TS. Evaluation of Global Hemostatic Assays in Response to Factor VIII Inhibitors. Clin Appl Thromb Hemost. 2019 Jan-Dec. 25:1076029619836171. [Medline]. [Full Text].
  14. Bachelet D, Albert T, Mbogning C, et al. Risk stratification integrating genetic data for factor VIII inhibitor development in patients with severe hemophilia A. PLoS One. 2019. 14 (6):e0218258. [Medline]. [Full Text].
  15. Peyvandi F, Cannavo A, Garagiola I, et al. Timing and severity of inhibitor development in recombinant versus plasma-derived factor VIII concentrates: a SIPPET analysis. J Thromb Haemost. 2018 Jan. 16 (1):39-43. [Medline]. [Full Text].
  16. Peyvandi F, Mannucci PM, Palla R, Rosendaal FR. SIPPET: methodology, analysis and generalizability. Haemophilia. 2017 May. 23 (3):353-61. [Medline].
  17. Sande CM, Al-Huniti A, Ten Eyck P, Sharathkumar AA. Impact of the Survey of Inhibitors in Plasma-Product Exposed Toddlers (SIPPET) study and its post hoc analyses on clinical practice in the United States: A survey of Haemophilia and Thrombosis Research Society members. Haemophilia. 2019 Jul 2. [Medline].
  18. Seligsohn U KK. Classification, Clinical Manifestations, and Evaluation of Disorders of Hemostasis. Prchal JT KK, Lichtman MA, Kipps TJ, Seligsohn U, ed. Williams Hematology. 8th ed. New York: McGraw-Hil; 2010.
  19. Nilsson IM, Jonsson S, Sundqvist SB, Ahlberg A, Bergentz SE. A procedure for removing high titer antibodies by extracorporeal protein-A-sepharose adsorption in hemophilia: substitution therapy and surgery in a patient with hemophilia B and antibodies. Blood. 1981 Jul. 58(1):38-44. [Medline].
  20. Field JJ, Fenske TS, Blinder MA. Rituximab for the treatment of patients with very high-titre acquired factor VIII inhibitors refractory to conventional chemotherapy. Haemophilia. 2007 Jan. 13(1):46-50. [Medline].
  21. Onitilo AA, Skorupa A, Lal A, Ronish E, Mercier RJ, Islam R. Rituximab in the treatment of acquired factor VIII inhibitors. Thromb Haemost. 2006 Jul. 96(1):84-7. [Medline].
  22. Berezne A, Stieltjes N, Le-Guern V, Teixeira L, Billy C, Roussel-Robert V. Rituximab alone or in association with corticosteroids in the treatment of acquired factor VIII inhibitors: report of two cases. Transfus Med. 2006 Jun. 16(3):209-12. [Medline].
  23. Wiestner A, Cho HJ, Asch AS, Michelis MA, Zeller JA, Peerschke EI. Rituximab in the treatment of acquired factor VIII inhibitors. Blood. 2002 Nov 1. 100(9):3426-8. [Medline].
  24. Kasper CK, Aledort L, Aronson D, Counts R, Edson JR, van Eys J. Proceedings: A more uniform measurement of factor VIII inhibitors. Thromb Diath Haemorrh. 1975 Nov 15. 34(2):612. [Medline].
  25. Inbal A, Bank I, Zivelin A, Varon D, Dardik R, Shapiro R. Acquired von Willebrand disease in a patient with angiodysplasia resulting from immune-mediated clearance of von Willebrand factor. Br J Haematol. 1997 Jan. 96(1):179-82. [Medline].

Залишити коментар

Ваша e-mail адреса не оприлюднюватиметься. Обов’язкові поля позначені *